Open access
Aug 2026
Targeting KRAS in Cancer: Advances in Precision Oncology and Drug Development
These breakthroughs have validated direct KRAS inhibition as an effective therapeutic strategy, however, durable clinical responses remain limited by intrinsic and acquired resistance, pathway reactivation, tumour heterogeneity, and the lack of effective therapies for non-G12C KRAS mutations.
Pasham Uma, Dandotikar Neha, R. Manisha et al.
· International Journal of Inn... · 0 citations